Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data

Area of Science:

• Immunology
• Vaccinology
• Public Health

Background:

• Antibody concentrations vary among pneumococcal conjugate vaccines (PCVs).
• Linking immunogenicity to vaccine effectiveness is crucial for next-generation vaccine assessment.
• Pneumococcal conjugate vaccines (PCVs) are vital for preventing invasive pneumococcal disease.

Purpose of the Study:

• To assess if antibody concentrations from next-generation PCVs can predict vaccine effectiveness.
• To establish a method for estimating protective antibody concentrations for pneumococcal serotypes.
• To validate predicted vaccine effectiveness against observed data.

Main Methods:

• Generated simulated reverse cumulative distribution curves using serotype-specific IgG concentrations.
• Combined IgG data with published vaccine effectiveness estimates for PCV7.
• Calculated protective antibody concentrations and predicted PCV13 effectiveness for shared serotypes.

Main Results:

• Predicted vaccine effectiveness for PCV13 closely matched observed effectiveness in the UK, Australia, and Germany.
• Median predicted effectiveness values were 93% vs. 90% (UK), 71% vs. 70% (Australia), and 91% vs. 90% (Germany).
• Demonstrated reliable estimation of vaccine effectiveness using IgG concentrations from next-generation PCVs.

Conclusions:

• Serotype-specific IgG concentrations from next-generation PCVs can reliably predict vaccine effectiveness.
• This method supports the evaluation of new pneumococcal conjugate vaccines.
• Immunogenicity data provides a valuable tool for estimating vaccine effectiveness against invasive pneumococcal disease.